Return to Comprehensive Heart Care Welcome Page
Audio-Visual Presentations
Twenty years ago we began to provide yearly, ten session, Integrative Cardiology presentations, designed for our patients and other interested parties. Over the past ten years we have relied on DVDs, either videos of my presentations or studio recorded projects, to convey information to our patients and other interested parties. This approach is time consuming and expensive. PowerPoint 2016 allows me to create voice over PowerPoint presentations at home, at my leisure, and with negligible cost. Thus I am in the process of creating voice over PowerPoints corresponding to the 20 hours of presentation that was given at Integrative Medicine training programs in 2017. Later, I will update some of our older DVD presentations within this format. The 2017 presentations are designed for Integrative Practitioners. Some of the biology will be new to you. Memorizing the details is not important, but I want all of you to understand the science behind my recommendations. A listing of new and old presentations is given below. Or, you can click on Dr. Roberts' U-Tube Page for access to these presentations.
Ouabain (Stropanthin-G) in Cardiovascular
Medicine - Integrative Practitioner Version
Ouabain serves as an effective, negligible risk approach to
coronary insufficiency, microvascular ischemia, atrial arrhythmia, and heart
failure. Ouabain, an endogenous adrenal/hypothalamic hormone, interacts
with a specific cell membrane receptor (Sodium/Potassium ATPase), to govern
multiple aspects of CV biology. Hyperinsulinemia (diabesity),
catecholamine (adrenalin), and oxidative stress states inhibit ATPase activity,
compromising CV health. Ouabain supplementation restores ATPase
expression, improving CV function and attenuating symptoms in a fashion that
cannot be recapitulated by man-made molecules. This presentation, designed
for the Integrative Practitioner, will review the physiology and history of
Ouabain and present case studies and clinical trials documenting Ouabain safety
and efficacy.
Polyenylphosphatidylcholine (PPC) in Cardiovascular Disease and Integrative
Medicine - Part One
PPC is our most effective anti-atherosclerotic therapy. Administered
orally or IV, PPC is taken up by the HDL particle, where it stimulates removal
of cholesterol from the vascular wall. PPC thus promotes reverse
cholesterol transport, regressing plaque and improving blood flow. PPC
will also be taken up by every cell in the body, where it improves cell membrane
function and provides protective anti-oxidative and anti-inflammatory effects.
PPC can be sonicated, and then admixed with the metal chelator EDTA, allowing
for concomitant metal detoxification. Clinical trials documenting the
benefit of PPC in lipid reduction and vascular disease will be presented, along
with case studies.
Polyenylphosphatidylcholine (PPC) in Cardiovascular Disease and Integrative
Medicine - Part Two
Part two will explore the anti-oxidative, anti-inflammatory, and cell protective
effects of PPC. Benefits of PPC in GI tract and liver disease states will
be discussed, along with potential benefits of PPC in neurologic disease, cancer
prevention, and as an anti-aging therapy.
CardioRheumatology - Focus on Colchicine (Fall
2017)
CardioRheumatology relates to the repurposing of agents traditionally used by
the Rheumatologist in the treatment of joint disease (Colchicine, Allopurinol,
Condroitin Sulfate, and Methotrexate) instead to resolve the oxidative and
inflammatory stress that underlies and drives cardiovascular disease, and
age-related degenerative disease in general. Unstable coronary disease and
acute gout share a common pathophysiology, one that we can block with
Colchicine. Learn how we can use Colchicine to lower CRP and other
inflammatory mediators in acute and chronic coronary disease, help prevent
recurrent atrial fib following ablation, and to dramatically decrease the risk
of heart attack and stroke in our patients.
CardioRheumatology - Focus on Allopurinol (Fall
2017)
Allopurinol blocks Xanthine Oxidase, the enzyme that converts Adenosine
(generated when ATP energy recycling falters) to Uric Acid, in this process
wasting Oxygen and generating Superoxide free radical. Xanthine Oxidase activity
is up regulated in coronary insufficiency, heart failure, fatty liver, diabetes,
and in other dysmetabolic conditions characterized by oxygen deficiency,
inflammation, and oxidative stress. Allopurinol blocks Xanthine Oxidase
activity, sparing oxygen and blunting superoxide generation. Learn how we
can use Allopurinol to relieve symptoms of coronary insufficiency, and improve
outcome following heart attack, acute coronary revascularization, and bypass
surgery. Allopurinol protects us from oxidative stress; thus Allopurinol will
protects us from vascular disease and kidney disease progression.
Allopurinol attenuates all components of the Metabolic Syndrome, which itself is
driven by oxidative stress.
CardioRheumatology - Focus on Chondroitin Sulfate
(Fall 2017)
Chondroitin Sulfate blunts Nuclear Kappa Beta translocation, thus blunting the
inflammation that characterizes atherosclerosis and autoimmune disease states.
Chondroitin Sulfate also blocks LDL trapping within the vascular wall. Learn how
we can use Chondroitin Sulfate to protect against heart attack and stroke, along
with the potential value of Chondroitin Sulfate in Psoriasis, Inflammatory Bowel
Disease, and other inflammatory conditions.
Chelation Therapy in Cardiovascular and Renal
Disease - Fall 2017 ACIM Meeting
Recent studies supporting the use of EDTA Chelation therapy in the treatment of
coronary disease and kidney disease are presented.
Lumbrokinase - Spring 2015 Advanced Integrative Cardiology Module 16E;
Fellowship in Anti-Aging and Regenerative Medicine
Lumbrokinase degrades fibrinogen and fibrin clot, in a fashion that does not
increase bleeding risk. Learn how we can use Lumbrokinase to regress
plaque and improve outcome following stroke, and to attenuate symptoms and
improve functional status in stable and unstable coronary insufficiency.
Integrative Cardiology for the Chelation Physician - Fall 2017 ACAM Chelation
Therapy training course.
This is a ten hour overview of Integrative Cardiology, designed for physicians
who are learning the science of Chelation Therapy (stated otherwise, this is
everything else that we do within the scope of Integrative Cardiology).
The presentation is divided in to five segments, as listed below.
Integrative Cardiology for the Chelation
Physician - Part One
Part One covers the key concepts of Oxidative Stress, Inflammatory Stress, and
Immune Dysregulation. The cause(s) of hyperlipidemia are discussed, as
well as the rationale for lipid lowering therapy. Endothelial Function
and Carotid Artery Intima-Media Thickness (IMT) are discussed as key physiologic
indicators of vascular health. The roles of Angiotensin Converting Enzyme
inhibition (ACEI) and Beta-Blocker therapy are discussed.
Integrative Cardiology for the Chelation
Physician - Part Two
Part Two covers CardioRheumatology (Colchicine, Allopurinol, and Chondroitin
Sulfate) as a means of attenuating the oxidative and inflammatory stress that
initiates and drives forward Cardiovascular and Kidney disease, and then
summarizes the main points of Parts One and Two.
Integrative Cardiology for the Chelation
Physician - Part Three
Part Three starts with an in depth description of our multimodal, integrative
approach to Oxidative Stress. This is followed by brief discussions of
Fish Oil supplementation, Vitamin D, Vitamin K2 to prevent vascular
calcification, EECP, Lipoprotein(a), Testosterone, and Lumbrokinase.
Integrative Cardiology for the Chelation
Physician - Part Four
Part Four starts with a discussion on the use of Berberine in Integrative
Cardiology (much more on Berberine below). "Bioenergetic Support for the
Tired and Energy Starved Heart" covers nutritional approaches to optimize
Mitochondrial Function and Cardiac Performance (Co-Enzyme Q10, Carnitine,
Ribose, Taurine, Terminalia, Thiamine, Magnesium, and Hawthorne Berry).
Cardiovascular Immune Modulation with Pentoxifylline, Reverse Cholesterol
Transport with Phosphatidylcholine, Organic Pollutant Toxicity, and Methyl Cycle
Dysfunction are briefly discussed.
Integrative Cardiology for the Chelation
Physician - Part Five
"Doctor I Can't Take a Statin" covers Nutraceutical Approaches to Lipid
Reduction (Red Yeast Rice Extract, Bergamot, Amla, and Delta Tocotrienol).
Factors that influence liver generation and clearing of LDL Cholesterol are
reviewed, along with the synergy between Berberine and all other agents that
lower Cholesterol. The five part presentation is then summarized.
An Introduction to Integrative Cardiology - Fall 2017 PCCA Meeting - Ninety minutes under construction
Ultraviolet Blood Irradiation - Part One
Ultraviolet Blood Irradiation - Part Two
Chronicles of Berberine (Summer 2014) - Three part presentation:
DVD One -
Berberine in Lipid Management
DVD Two -
Berberine in Diabetes Management and Berberine in Inflammation (Part One)
DVD Three -
Berberine in Inflammation (Part Two) and Berberine in Cardiovascular Disease
Carotid Artery Intima-Media Thickness (IMT) - Part One
Carotid Artery Intima-Media Thickness (IMT) - Part Two
Testosterone - The Heart Hormone for Men - Part One
Testosterone - The Heart Hormone for Men - Part Two
Enhanced External Counterpulsation (EECP)
Drug and Device Approaches to Heart Failure and Post-Heart Attack Outcome
Nutritional Approaches to Heart Failure and Post-Heart Attack Outcome
EDTA Chelation Therapy in Cardiovascular Disease (2007)
Mercury - Biochemistry, Toxicity, and Treatment - Part One
Mercury -
Biochemistry, Toxicity, and Treatment - Part Two
Immune Mechanisms of Atherosclerosis and Heart
Failure - Part One
Immune Mechanisms of Atherosclerosis and Heart Failure - Part Two
Immune Mechanisms of Atherosclerosis and Heart Failure - Part Three
Antioxidant Vitamins - The Cornerstone of Nutritional Cardiology (2007)